Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Companies / Oculis
Entity

Oculis

Tracked across 4 events · 44 articles · First seen May 29, 2026 · Last active Jun 11, 2026

Sentiment
-12
Attention
4
Events
4
Relationships
4
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (4)
2 20
Business
Oculis to Present at Goldman Sachs Conference
Oculis, a global biopharmaceutical company, announced its management's participation in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 9, 2026, in Miami, FL. Dr. Riad Sherif, CEO of Oculis,…
Impact: Oculis will present its late-stage portfolio and pipeline updates at the conference, potentially increasing investor interest and its stock value.
Jun 08, 2026 · 6 articles
4 -70
Business
Oculis OCS-01 DME trial fails
Oculis announced disappointing topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 eye drops in patients with diabetic macular edema (DME). The primary endpoint of improved best corrected visual acuity was not…
Impact: Oculis announced that its OCS-01 eye drops failed to meet the primary endpoint in Phase 3 trials for diabetic macular edema (DME), leading to a decision not to pursue FDA regulatory filing for this indication. This negatively impacts Oculis's stock and future revenue expectations for OCS-01 in DME.
May 29, 2026 · 18 articles
4 70
Tech
Oculis Presents Privosegtor Optic Neuritis Data
Oculis announced an upcoming presentation at Clinical Trials at the Summit 2026, where its CEO, Riad Sherif, will highlight the development journey of Privosegtor. Privosegtor is a novel peptoid small molecule with the potential to…
Impact: Oculis is presenting its Privosegtor program at a major clinical trials summit, highlighting its progress in developing a potential neuroprotective therapy for optic neuritis, which could significantly benefit the company.
Jun 11, 2026 · 7 articles
4 -70
Regulatory
Oculis Securities Fraud Investigation
Pomerantz LLP is investigating Oculis for potential securities fraud and other unlawful business practices. This investigation follows Oculis's announcement on May 29, 2026, that its lead drug candidate, OCS-01, failed to meet primary endpoints in…
Impact: Oculis is facing an investigation for securities fraud after its lead drug candidate, OCS-01, failed two late-stage trials, causing a significant drop in its stock price.
Jun 02, 2026 · 13 articles
Key Actions (11)
100 Oculis announced topline resultsOculis OCS-01 DME trial fails
100 The Schall Law Firm announced investigation OculisOculis Securities Fraud...
95 Oculis announced topline resultsOculis Securities Fraud...
95 Oculis did not meet endpointOculis OCS-01 DME trial fails
95 Pomerantz LLP investigated claims OculisOculis Securities Fraud...
90 Oculis will not pursue filing United States — Food and Drug AdministrationOculis OCS-01 DME trial fails
90 Oculis will not pursue filing United States — Food and Drug AdministrationOculis Securities Fraud...
90 Oculis announced participationOculis to Present at...
90 Oculis announced presentationOculis Presents...
80 Oculis will focus resourcesOculis OCS-01 DME trial fails
60 Levi & Korsinsky initiated investigation OculisOculis OCS-01 DME trial fails
Relationships (4)
Riad Sherif ↔ Oculis
Riad Sherif ↔ Oculis
United States — Food and Drug Administration ↔ Oculis
United States — Food and Drug Administration ↔ Oculis
NEWSDESK
Track Oculis live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.